Straits Times Index
3,205.14 +16.64 (+0.52%) Nikkei
28,804.85 +96.27 (+0.34%) Hang Seng
26,126.93 +109.40 (+0.42%) FTSE 100
7,204.55 +14.25 (+0.20%) BTC-USD
61,326.13 -1,737.65 (-2.76%) CMC Crypto 200
1,453.34 -49.69 (-3.31%)
Eupraxia Pharmaceuticals Inc. (EPRX.TO)
| Previous close | 2.5000 |
| Open | 2.2300 |
| Bid | 2.2800 x N/A |
| Ask | 2.5000 x N/A |
| Day's range | 2.2000 - 2.4700 |
| 52-week range | 2.1000 - 7.7500 |
| Volume | 27,817 |
| Avg. volume | 10,162 |
| Market cap | 32.188M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8210 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.38 |
- CNW Group
Eupraxia Pharmaceuticals Inc. Provides Update for Phase 2 Osteoarthritis Drug Candidate EP-104IAR
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform technology, today announced an update for its lead osteoarthritis (OA) drug candidate EP-104IAR.
- CNW Group
Eupraxia Pharmaceuticals Inc. Commences Patient Screening For Its Phase 2 Trial For Osteoarthritis Drug Candidate EP-104IAR
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform technology, today announced that it has started screening patients for inclusion into its Phase 2 trial, which is evaluating EP-104IAR's efficacy and safety as a treatment for knee osteoarthritis.
- CNW Group
Eupraxia Pharmaceuticals Inc. Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery platform technology, today announced that senior management will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference, held virtually September 13-15, 2021.
